These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
339 related articles for article (PubMed ID: 30253174)
1. Occupancy of adenosine A Ishibashi K; Miura Y; Wagatsuma K; Toyohara J; Ishiwata K; Ishii K Neuropharmacology; 2018 Dec; 143():106-112. PubMed ID: 30253174 [TBL] [Abstract][Full Text] [Related]
2. In Vivo Evaluation of Zhou X; Boellaard R; Ishiwata K; Sakata M; Dierckx RAJO; de Jong JR; Nishiyama S; Ohba H; Tsukada H; de Vries EFJ; Elsinga PH J Nucl Med; 2017 May; 58(5):762-767. PubMed ID: 28062599 [No Abstract] [Full Text] [Related]
3. Istradefylline: adenosine A2A receptor antagonist to reduce "OFF" time in Parkinson's disease. Paton DM Drugs Today (Barc); 2020 Feb; 56(2):125-134. PubMed ID: 32163528 [TBL] [Abstract][Full Text] [Related]
4. Adenosine 2A receptor occupancy by tozadenant and preladenant in rhesus monkeys. Barret O; Hannestad J; Alagille D; Vala C; Tavares A; Papin C; Morley T; Fowles K; Lee H; Seibyl J; Tytgat D; Laruelle M; Tamagnan G J Nucl Med; 2014 Oct; 55(10):1712-8. PubMed ID: 25082853 [TBL] [Abstract][Full Text] [Related]
5. Initial Evaluation of an Adenosine A Sakata M; Ishibashi K; Imai M; Wagatsuma K; Ishii K; Zhou X; de Vries EFJ; Elsinga PH; Ishiwata K; Toyohara J J Nucl Med; 2017 Sep; 58(9):1464-1470. PubMed ID: 28280214 [No Abstract] [Full Text] [Related]
6. Adenosine A(2A) receptors measured with [C]TMSX PET in the striata of Parkinson's disease patients. Mishina M; Ishiwata K; Naganawa M; Kimura Y; Kitamura S; Suzuki M; Hashimoto M; Ishibashi K; Oda K; Sakata M; Hamamoto M; Kobayashi S; Katayama Y; Ishii K PLoS One; 2011 Feb; 6(2):e17338. PubMed ID: 21386999 [TBL] [Abstract][Full Text] [Related]
7. The role of istradefylline in the Parkinson's disease armamentarium. Müller T Expert Opin Pharmacother; 2023 May; 24(7):863-871. PubMed ID: 37029952 [TBL] [Abstract][Full Text] [Related]
8. Evaluating the impact of adjunctive istradefylline on the cumulative dose of levodopa-containing medications in Parkinson's disease: study protocol for the ISTRA ADJUST PD randomized, controlled study. Hatano T; Kano O; Sengoku R; Yoritaka A; Suzuki K; Nishikawa N; Mukai Y; Nomura K; Yoshida N; Seki M; Matsukawa MK; Terashi H; Kimura K; Tashiro J; Hirano S; Murakami H; Joki H; Uchiyama T; Shimura H; Ogaki K; Fukae J; Tsuboi Y; Takahashi K; Yamamoto T; Yanagisawa N; Nagayama H BMC Neurol; 2022 Mar; 22(1):71. PubMed ID: 35241003 [TBL] [Abstract][Full Text] [Related]
9. Istradefylline - a first generation adenosine A Jenner P; Mori A; Aradi SD; Hauser RA Expert Rev Neurother; 2021 Mar; 21(3):317-333. PubMed ID: 33507105 [No Abstract] [Full Text] [Related]
10. Two new adenosine receptor antagonists for the treatment of Parkinson's disease: istradefylline versus tozadenant. Perez-Lloret S; Merello M Expert Opin Pharmacother; 2014 Jun; 15(8):1097-107. PubMed ID: 24673462 [TBL] [Abstract][Full Text] [Related]
11. Istradefylline, a novel adenosine A2A receptor antagonist, for the treatment of Parkinson's disease. Jenner P Expert Opin Investig Drugs; 2005 Jun; 14(6):729-38. PubMed ID: 16004599 [TBL] [Abstract][Full Text] [Related]
12. Efficacy of adenosine A2A receptor antagonist istradefylline as augmentation for Parkinson's disease: a meta-analysis of randomized controlled trials. Tao Y; Liang G Cell Biochem Biophys; 2015 Jan; 71(1):57-62. PubMed ID: 25096504 [TBL] [Abstract][Full Text] [Related]
13. Altered adenosine 2A and dopamine D2 receptor availability in the 6-hydroxydopamine-treated rats with and without levodopa-induced dyskinesia. Zhou X; Doorduin J; Elsinga PH; Dierckx RAJO; de Vries EFJ; Casteels C Neuroimage; 2017 Aug; 157():209-218. PubMed ID: 28583881 [TBL] [Abstract][Full Text] [Related]
14. Istradefylline for the treatment of Parkinson's disease. Park A; Stacy M Expert Opin Pharmacother; 2012 Jan; 13(1):111-4. PubMed ID: 22149371 [TBL] [Abstract][Full Text] [Related]
15. Effect of dopaminergic medication on adenosine 2A receptor availability in patients with Parkinson's disease. Waggan I; Rissanen E; Tuisku J; Matilainen M; Helin S; Parkkola R; Rinne JO; Airas L Parkinsonism Relat Disord; 2021 May; 86():40-44. PubMed ID: 33831661 [TBL] [Abstract][Full Text] [Related]
16. Adenosine A2A receptor antagonist istradefylline reduces daily OFF time in Parkinson's disease. Mizuno Y; Kondo T; Mov Disord; 2013 Jul; 28(8):1138-41. PubMed ID: 23483627 [TBL] [Abstract][Full Text] [Related]
17. Adenosine A2A receptor antagonist istradefylline (KW-6002) reduces "off" time in Parkinson's disease: a double-blind, randomized, multicenter clinical trial (6002-US-005). LeWitt PA; Guttman M; Tetrud JW; Tuite PJ; Mori A; Chaikin P; Sussman NM; Ann Neurol; 2008 Mar; 63(3):295-302. PubMed ID: 18306243 [TBL] [Abstract][Full Text] [Related]
18. Istradefylline for Parkinson's disease patients experiencing motor fluctuations: results of the KW-6002-US-018 study. Pourcher E; Fernandez HH; Stacy M; Mori A; Ballerini R; Chaikin P Parkinsonism Relat Disord; 2012 Feb; 18(2):178-84. PubMed ID: 22000279 [TBL] [Abstract][Full Text] [Related]
19. Adenosine 2A receptor availability in dyskinetic and nondyskinetic patients with Parkinson disease. Ramlackhansingh AF; Bose SK; Ahmed I; Turkheimer FE; Pavese N; Brooks DJ Neurology; 2011 May; 76(21):1811-6. PubMed ID: 21606452 [TBL] [Abstract][Full Text] [Related]
20. Istradefylline, an adenosine A₂A receptor antagonist, for patients with Parkinson's Disease: a meta-analysis. Chen W; Wang H; Wei H; Gu S; Wei H J Neurol Sci; 2013 Jan; 324(1-2):21-8. PubMed ID: 23085003 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]